First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0.
Markowitz J, Shamblott M, Brohl AS, Sarnaik AA, Eroglu Z, Khushalani NI, Dukes CW, Chamizo A, Bastawrous M, Garcia ET, Dehlawi A, Chen PL, De Aquino DB, Sondak VK, Tarhini AA, Kim Y, Lawman P, Pilon-Thomas S.
Markowitz J, et al. Among authors: garcia et.
Mol Cancer Ther. 2024 Aug 1;23(8):1139-1143. doi: 10.1158/1535-7163.MCT-23-0652.
Mol Cancer Ther. 2024.
PMID: 38657233
Free PMC article.
Clinical Trial.